Interview with Rob Panting, General Manager Rentschler ATMP in Scrip: “Closing The Gaps In Gene Therapy Production”

The growing pace of approvals in the advanced therapy medicinal products (ATMP) sector is testament to the impact this part of the biopharma industry is having on improving and saving patients’ lives. But, the sheer "volume” of scientific ideas for therapeutic ATMP approaches is far exceeding the available production capacity - even for pilot-scale manufacturing. The result is a growing need for experts in both process development and manufacturing to ensure new ATMP therapies reach the market swiftly with no production hold ups during the clinical and regulatory processes.

Rob Panting, our general manager Rentschler ATMP, recently spoke to Scrip about the critical work he and his team are undertaking in Stevenage, UK, Europe’s largest gene and cell therapy cluster.

Looking at 2023, Rentschler ATMP is preparing for big advancements. “Already, we provide the vital AAV services to our clients and are ready for process development. In addition to the cGMP-capable production suites, we have fully equipped laboratory space for process development and quality control. Very soon, though, Rentschler ATMP will also offer other types of gene vectors and will evaluate cutting-edge technologies to support the industry and help provide novel therapeutics to patients,” Panting added.

Read the full article here: https://scrip.pharmaintelligence.informa.com/SC147363/Closing-The-Gaps-In-Gene-Therapy-Production